RT Journal Article SR Electronic T1 COPD Population in US Primary Care: Data From the Optimum Patient Care DARTNet Research Database and the Advancing the Patient Experience in COPD Registry JF The Annals of Family Medicine JO Ann Fam Med FD American Academy of Family Physicians SP 319 OP 327 DO 10.1370/afm.2829 VO 20 IS 4 A1 Pace, Wilson D. A1 Brandt, Elias A1 Carter, Victoria A. A1 Chang, Ku-Lang A1 Edwards, Chelsea L. A1 Evans, Alexander A1 Fox, Chester A1 Gaona, Gabriela A1 Han, MeiLan K. A1 Kaplan, Alan G. A1 Kent, Rachel A1 Kocks, Janwillem W. H. A1 Kruszyk, Maja A1 Le Lievre, Chantal E. A1 Li Voti, Tessa A1 Mahle, Cathy A1 Make, Barry A1 Ratigan, Amanda R. A1 Shaikh, Asif A1 Skolnik, Neil A1 Stanley, Brooklyn A1 Yawn, Barbara P. A1 Price, David B. YR 2022 UL http://www.annfammed.org/content/20/4/319.abstract AB PURPOSE To describe demographic and clinical characteristics of chronic obstructive pulmonary disease patients managed in US primary care.METHODS This was an observational registry study using data from the Chronic Obstructive Pulmonary Disease (COPD) Optimum Patient Care DARTNet Research Database from which the Advancing the Patient Experience COPD registry is derived. Registry patients were aged ≥35 years at diagnosis. Electronic health record data were collected from both registries, supplemented with patient-reported information/outcomes from the Advancing the Patient Experience registry from 5 primary care groups in Texas, Ohio, Colorado, New York, and North Carolina (June 2019 through November 2020).RESULTS Of 17,192 patients included, 1,354 were also in the Advancing the Patient Experience registry. Patients were predominantly female (56%; 9,689/17,192), White (64%; 9,732/15,225), current/ex-smokers (80%; 13,784/17,192), and overweight/obese (69%; 11,628/16,849). The most commonly prescribed maintenance treatments were inhaled corticosteroid with a long-acting β2-agonist (30%) and inhaled corticosteroid with a long-acting muscarinic antagonist (27%). Although 3% (565/17,192) of patitents were untreated, 9% (1,587/17,192) were on short-acting bronchodilator monotherapy, and 4% (756/17,192) were on inhaled corticosteroid monotherapy. Despite treatment, 38% (6,579/17,192) of patients experienced 1 or more exacerbations in the last 12 months. These findings were mirrored in the Advancing Patient Experience registry with many patients reporting high or very high impact of disease on their health (43%; 580/1,322), a breathlessness score 2 or more (45%; 588/1,315), and 1 or more exacerbation in the last 12 months (50%; 646/1,294).CONCLUSIONS Our findings highlight the high exacerbation, symptom, and treatment burdens experienced by COPD patients managed in US primary care, and the need for more real-life effectiveness trials to support decision making at the primary care level.